Fig. 2

Characterization of tumor-infiltrating immune cells in WT and Tyr^−/− B16-F10 melanoma model. A Representative images of WT and Tyr^−/− B16-F10 tumors from female C57BL/6 mice on day 14. B The weight of WT and Tyr^−/− B16-F10 tumors on day 14. C The immune infiltration profiling in WT and Tyr^−/− B16-F10 tumors through scRNA-Seq. CD45⁺ immune cells from WT and Tyr^−/− B16-F10 tumors were sorted and analyzed. Pooled samples from three mice per group were used. Dimensionality reduction was done with the t-SNE algorithm and cell clustering using Seurat. Each cluster was denoted a unique color. t-SNE, t-distributed stochastic neighbor embedding. D Proportions of different immune cell types in WT and Tyr^−/− B16-F10 tumors. E Gating strategy for tumor-infiltrating immune cells, including CD11b⁺ cells and T cells, in WT and Tyr^−/− B16-F10 tumors. Cells were gated based on CD45⁺, CD11b⁺, CD19⁺, CD3⁺ TCR-β⁺, CD4⁺, and CD8⁺ markers. F Quantification of tumor-infiltrating CD45⁺ cells in WT and Tyr^−/− B16-F10 tumors. G The proportion of T cells, CD4⁺ T cells and CD8⁺ T cells among tumor-infiltrating CD45⁺ cells in WT and Tyr^−/− B16-F10 tumors. H Proportion of CD11b⁺ cells among tumor-infiltrating CD45⁺ cells in WT and Tyr^−/− B16-F10 tumors. I-J Cell counts of T cells, CD4⁺ T cells, CD8⁺ T cells (I), and CD11b⁺ cells (J) per gram of tissue in WT and Tyr^−/− B16-F10 tumors. Data are presented as mean ± SEM (WT tumors, n = 9; Tyr^−/− tumors, n = 8 or 9). All data are pooled from two independent experiments. Statistical significances were calculated using Student’s t-test (* p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant)